Use of any vaccines against infectious diseases (e.g. influenza, varicella, pneumococcus) within weeks of initiation of study treatment. Within days of treatment initiation:\r\nPlatelets >= ,/mcL The patients' last dose of chemotherapy must be at least weeks prior to initiation of study therapy Treatment with radiation therapy within weeks prior to the initiation of study drug. Within days of treatment initiation:\r\nPlatelets >= ,/mcL Treatment with investigational therapy within days prior to initiation of study treatment Patients who have had chemotherapy (e.g., purine analogues, alkylating agents), radiation therapy, or participation in any investigational drug treatment within weeks of initiation of DMF or at any time during the study No prior lapatinib within days prior to initiation of protocol treatment Treatment with investigational therapy within days prior to initiation of study treatment Had immunotherapy, radiotherapy, radioimmunotherapy, biological therapy, chemotherapy, or treatment with an investigational product within weeks prior to treatment initiation (or oral therapy within week prior to treatment initiation). Treatment with radiation therapy within weeks prior to the initiation of study drug administration. Participant is able to complete a minimum of days of study agent dosing prior to initiation of definitive treatment for their cancer Use of any vaccines against infectious diseases within weeks of initiation of study treatment. Investigational therapy within days prior to initiation of study treatment Patients who have had chemotherapy (e.g., purine analogues, alkylating agents), immunotherapy, radiation therapy, or participation in any investigational drug treatment within weeks of initiation of UC-, or at any time during the study Between days and post transplantation at the time of initiation of the study drug Patients must be off all disease modifying therapy for MDS for days prior to initiation of study treatment; patients may receive hydrocortisone prophylactically to prevent transfusion reactions Previous cytotoxic therapies, including cytotoxic investigational agents, for multiple myeloma within weeks ( weeks for nitrosoureas) prior to initiation of therapy. The use of live vaccines within days before initiation of therapy. IMiDs, PIs and or corticosteroids within weeks prior to initiation of therapy. Other investigational therapies and monoclonal antibodies (mAb) within weeks of initiation of therapy Prednisone up to but no more than mg orally once daily (q.d.) or its equivalent for symptom management of comorbid conditions is permitted but dose should be stable for at least days prior to initiation of therapy Prior major surgical procedure or radiation therapy within weeks of initiation of therapy (this does not include limited course of radiation used for management of bone pain within days of initiation of therapy) Treatment with any of the drugs listed in Section .. at the time of study treatment initiation. Treatment with any, investigational therapy within the weeks prior to the initiation of study drug administration Administration of investigational agents within days prior to treatment initiation Indication for initiation of therapy Herbal preparations are not allowed throughout the study, and should be discontinued days prior to initiation of study treatment Have received any unapproved agent or device within days before initiation of study treatment. All patients must discontinue anti-platelet agents or anticoagulants days prior to initiation of study drug Current or previous treatment with investigational therapy in another therapeutic clinical trial interrupted less than weeks before study treatment initiation. Use of any vaccines against infectious diseases (e.g. varicella, pneumococcus) within weeks of initiation of study treatment. Patient received investigational treatment within weeks or immunotherapy or antibody therapy within days prior to initiation of treatment with Toca , and/or has not recovered from toxicities associated with such treatment. Surgery prior to enrollment within days prior to the initiation of study treatment or unhealed surgical incision; Patients must have stable topical medication regimen for weeks prior to study initiation History of treatment with canakinumab within the months prior to study initiation History of phototherapy within weeks prior to study initiation Loco-regional treatment within weeks prior to initiation of study treatment. Any anti-lymphoma treatment within months of treatment initiation. Last chemotherapy at least weeks from initiation of study treatment Treatment with systemic immunosuppressive medication within weeks prior to initiation of study Have received any unapproved agent or device within days before initiation of study treatment. Treatment with radiation therapy within weeks prior to the initiation of study drug administration. Received the following within days prior to the initiation of study treatment: Treatment with investigational therapy within days prior to initiation of study drug Investigational therapy within days prior to initiation of study treatment Any cytotoxic or biologic therapy less than weeks prior to initiation of therapy. Therapy with other investigational agents within weeks of treatment initiation on this trial Immunosuppressive therapy within days prior to initiation of protocol therapy Immunosuppressive therapy within days prior to initiation of protocol therapy Prior recent systemic or investigational therapy within days of initiation of study treatment; an exception is that EGFR inhibitor may be continued up until days of initiation of study treatment Participant treated with any prior systemic therapy for myeloma; treatment by localized radiotherapy is not an exclusion criterion if an interval of at least days between the end of radiotherapy and initiation of protocol therapy is observed; intervals of less than days between radiotherapy and initiation of protocol therapy will be considered on a case by case basis with the lead principal investigator (PI), provided toxicity is not a concern; similarly, the dose of corticosteroids received by the participant as part of initial therapy for myeloma should not exceed the equivalent of mg of dexamethasone over a two-week period before initiation of protocol therapy Subjects who have completed sipuleucel-T (Provenge ) treatment within days of study drug initiation. Radiotherapy within the weeks before initiation of treatment. Palliative radiation treatment to nonindex or bone lesions performed less than weeks before treatment initiation may be considered with medical monitor approval Participant treated with any prior systemic therapy with the exception of the following:\r\n* Treatment by localized radiotherapy for a specific indication within weeks of initiation of treatment\r\n* Treatment with corticosteroids, not to exceed the equivalent of mg of dexamethasone over a four-week period before initiation of protocol therapy Patients who have received chemotherapy within weeks prior to the initiation of study treatment, or endocrine therapy within weeks prior to the initiation of study treatment; if patients are already on trastuzumab, this medication may be continued Patients who have participated in a prior investigational study within weeks prior to initiation of study treatment Toxicities due to prior cancer therapy that have not resolved before the initiation of study treatment, if the Investigator determines that the continuing complication will compromise the safe treatment of the patient Treatment with chemotherapy (other than high-dose chemotherapy as described above) or differentiation therapy (such as retinoic acid) or immunotherapy (such as anti-GD antibody treatment) within weeks prior to initiation of study drug or, if treatment included nitrosoureas, within weeks prior to initiation of study drug Treatment with investigational therapy (with the exception of cancer therapies as described above) within weeks prior to initiation of study drug Treatment with herbal cancer therapy within week prior to initiation of study drug Treatment for the studied cancer within days prior to initiation of study treatment Treatment with investigational therapy within days prior to initiation of study treatment Use of any vaccines against infectious diseases (e.g., influenza, varicella, etc.) within weeks ( days) of initiation of study therapy and days after the last administration of the study medication. Any investigation agents must be discontinued at least days prior to study treatment initiation Participation in an investigational anti-cancer study within weeks prior to initiation of therapy Subjects must be off any steroids days prior to the initiation of treatment Positive culture for or other clinical evidence of infection with bacteria or fungus within days of the initiation of study treatment Subjects must not have received other antineoplastic agents with therapeutic intent, excluding hydroxyurea and antimetabolites administered as part of maintenance chemotherapy, within days prior to study treatment initiation Patients who have received chemotherapy or radiotherapy within weeks prior to enrollment are NOT eligible for participation \r\n* The exception to this is patients who are refractory to conventional initial induction chemotherapy (=< courses) or to radiation; patients must have morphologic proof (from bone marrow aspirate, smears, or touch preps of marrow biopsy) of AML with > % blasts within weeks prior to initiation of study therapy\r\n* The last dose of cytotoxic therapy (NOT including Hydrea, which is allowed) must have been given >= days prior to initiation of study therapy\r\n* The last dose of biologic therapy must have been given >= days prior to initiation of study therapy\r\n* The last dose of any investigational agent must have been given >= days prior to initiation of study therapy Treatment initiation with BST no longer than months prior to randomization Within weeks of treatment initiation (day ), have received treatment with:\r\n* Imiquimod\r\n* Total body electron beam radiation\r\n* Investigational drugs or treatments Radiation therapy within weeks prior to initiation of study treatment Interval >= weeks between open brain biopsy and initiation of protocol-based therapy Date of randomization must be within weeks of initiation of optimal systemic therapy Patients must be off all \statin\ drugs for ? weeks prior to initiation of therapy. History of receiving any investigational treatment within days of study medication initiation Patients who have received prior lenalidomide therapy are not eligible for this study; further there should be at least a -day window from the patients last prior therapy before initiation of treatment on clinical trial Initiation of anti-tumor therapy including chemotherapy or investigational drug treatment within days before beginning study Patients may not have had radiation therapy within the last weeks prior to initiation of study treatment. Patients must not have the following foods/ supplements at least days prior to initiation of and during study treatment: Initiation of a new drug therapy within the past days prior to study commencement All patients are expected to be followed for at least year after the initiation of therapy All pre-treatment laboratory tests and scans must be performed within days prior to initiation of treatment Treatment with any anti-cancer therapy within weeks prior to initiation of study treatment Treatment with any anti-cancer therapy within weeks prior to initiation of study treatment No immunosuppressive therapy within days prior to initiation of protocol therapy Bilirubin =< . x ULN, within days prior to initiation of study drug Subjects who received any of the following within the last days of initiation of study treatment: ) Plasmapheresis, ) Major surgery, ) Radiation therapy, ) Use of any anti-myeloma drug therapy The last dose of biologic or investigational therapy must be =< days prior to initiation of study therapy Patient participants must be at a point of treatment initiation/change or evaluation for treatment initiation/change Within the first weeks of initiation of a new type of therapy Use of any vaccines against infectious diseases (e.g. varicella, pneumococcus) within weeks of initiation of study treatment. Initiation of investigational agent =< days after initiation of radiotherapy Patients must be able to complete the baseline S FACT EGFRI within days prior to initiation of EGFRI therapy Initiation of hormone therapy < weeks prior to enrollment in the study Anticipated initiation of cetuximab treatment with or without additional chemotherapy Use of any systemic antifungal therapy for > hours during the week prior to study drug initiation Has vomited in the hours prior to chemotherapy initiation on Treatment Day Had at least days for prior treatment to clear the body before initiation of DS-b administration (except for hydroxyurea that needs only days for clearance) Discontinuation of all other therapies (including radiotherapy or chemotherapy) for the treatment of iNHL >= weeks before initiation of study treatment Have discontinued all disease-modifying therapy for the primary cancer for days prior to initiation of study treatment. Baseline (prior to the initiation of new ET), and; Subsequently at , , and months after the initiation of therapy, and/or; Pregnant or actively breastfeeding without intention to discontinue prior to initiation of study